By Alexander Bueso
Date: Wednesday 25 May 2016
LONDON (ShareCast) - (ShareCast News) - Circassia Pharmaceuticals kicked off phase-three trials for its grass allergy treatment, the second imunotherapy programme for which it was seeking regulatory approval, and said it was on-track to report the results of its phase-three clinical trials for its Cat allergy treatment using its SPIRE technology platform.
The latest phase-three test was broken into two parts, with results form Part A due in the second half of 2017 and those from Part B, which would be conducted on a larger population size, due in the backhalf of 2018.
Analysts at Numis viewed that staging of the Grass-SPIRE test as a means to also factor in the results of the Phase three Cat-SPIRE trial into Grass-SPIRE.
"In the event of a failure, Circassia has a fast-growing specialty asthma diagnostics platform broad pipeline of respiratory generics and a solid balance sheet, and we continue to see an attractive risk reward profile with a 610p target price if successful and 177p if unsuccessful with further upside from the diagnostics (primary care) and generics (generic Advair and novel triple) portfolio on a 12-month view," Numis analysts Paul Cuddon, Sally Taylor and Stefan Hamill said in a research note sent to clients.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 73.80p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 75.20 |
52 Week Low | 54.00 |
Volume | 0 |
Shares Issued | 422.05m |
Market Cap | £311.47m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 2 |
Buy | 2 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 5 |
Latest | Previous | |
---|---|---|
Final | Special | |
Ex-Div | 23-May-24 | 17-Aug-23 |
Paid | 24-Jun-24 | 15-Sep-23 |
Amount | 1.00p | 2.50p |
You are here: research